Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;28(12):1290-1297.
doi: 10.1111/iju.14683. Epub 2021 Sep 8.

Glypican-1 as a target for fluorescence molecular imaging of bladder cancer

Dmitry M Polikarpov  1 , Douglas H Campbell  2 , Alexander B Zaslavsky  3 , Maria E Lund  2 , Angela Wu  2 , Yanling Lu  2 , Ganesh S Palapattu  3 , Bradley J Walsh  2 , Andrei V Zvyagin  4   5 , David A Gillatt  1
Affiliations
Free article

Glypican-1 as a target for fluorescence molecular imaging of bladder cancer

Dmitry M Polikarpov et al. Int J Urol. 2021 Dec.
Free article

Abstract

Objectives: To investigate whether anti-glypican-1 antibody Miltuximab conjugated with near-infrared dye IRDye800CW can be used for in vivo fluorescence imaging of urothelial carcinoma.

Methods: The conjugate, Miltuximab-IRDye800CW, was produced and characterized by size exclusion chromatography and flow cytometry with glypican-1-expressing cells. Balb/c nude mice bearing subcutaneous urothelial carcinoma xenografts were intravenously injected with Miltuximab-IRDye800CW or control IgG-IRDye800CW and imaged daily by fluorescence imaging. After 10 days, tumors and major organs were collected for ex vivo study of the conjugate biodistribution, including its accumulation in the tumor.

Results: The intravenous injection of Miltuximab-IRDye800CW to tumor-bearing mice showed its specific accumulation in the tumors with the tumor-to-background ratio of 12.7 ± 2.4, which was significantly higher than that in the control group (4.6 ± 0.9, P < 0.005). The ex vivo imaging was consistent with the in vivo findings, with tumors from the mice injected with Miltuximab-IRDye800CW being significantly brighter than the organs or the control tumors.

Conclusions: The highly specific accumulation and retention of Miltuximab-IRDye800CW in glypican-1-expressing tumors in vivo shows its high potential for fluorescence imaging of urothelial carcinoma and warrants its further investigation toward clinical translation.

Keywords: fluorescence-guided surgery; glypican-1; molecular imaging; monoclonal antibodies; urinary bladder neoplasms.

PubMed Disclaimer

References

    1. Burger M, Catto JWF, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013; 63: 234-41.
    1. Babjuk M, Böhle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. 2017; 71: 447-61.
    1. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J. Urol. 2000; 164(3 Part 1): 685-9.
    1. Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics 2014; 32: 1093-104.
    1. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early? J. Urol. 2001; 165: 808-10.

Publication types